A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.

This study also assessed Overall survival (OS); Overall response rate (ORR) as assessed by IRR; PFS as assessed by the investigator; Disease control rate (DCR) as assessed by IRR; Duration of Response (DOR) by IRR; Safety of ASP8273; and Quality of Life (QOL) and patient-reported outcome (PRO) parameters.

Study Overview

• Status: Terminated
• Conditions: Non-small Cell Lung Cancer (NSCLC)
• Intervention / Treatment: Drug: naquotinib mesilate; Drug: Erlotinib; Drug: Gefitinib

• Study Type: Interventional
• Enrollment (Actual): 530
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Site AU61003
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • Site AU61007
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Site AU61005
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Site AU61008
    • Fitzroy, Victoria, Australia, 3065
      • Site AU61002
    • Footscray, Victoria, Australia, 3011
      • Site AU61004
• Belgium
  • West-Vlaanderen
    • Gent, West-Vlaanderen, Belgium, 9000
      • Site BE32002
• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2C4
      • Site CA15006
  • Quebec
    • Montreal, Quebec, Canada, H49 1C5
      • Site CA15002
• Chile
  • Región Metropolitana De Santia
    • Santiago, Región Metropolitana De Santia, Chile, 8380455
      • Site CL56001
  • Valparaíso
    • Vina del Mar, Valparaíso, Chile, 2520612
      • Site CL56002
    • Vina del Mar, Valparaíso, Chile, 2540364
      • Site CL56007
• France
  • Gironde
    • Pessac, Gironde, France, 33604
      • Site FR33010
  • Hauts-de-Seine
    • Suresnes, Hauts-de-Seine, France, 92150
      • Site FR33011
  • Ilej-de-France
    • Creteil, Ilej-de-France, France, 94010
      • Site FR33003
  • Indre-et-Loire
    • Tours, Indre-et-Loire, France, 37044
      • Site FR33004
  • Isère
    • Grenoble, Isère, France, 38043
      • Site FR33006
  • Loire
    • Saint Priest en Jarez, Loire, France, 42270
      • Site FR33009
  • Pyrénées-Atlantiques
    • Bayonne, Pyrénées-Atlantiques, France, 64100
      • Site FR33012
  • Rhône
    • Pierre Benite, Rhône, France, 69310
      • Site FR33007
• Germany
  • Baden-Württemberg
    • Freiburg, Baden-Württemberg, Germany, 79106
      • Site DE49008
    • Karlsruhe, Baden-Württemberg, Germany, 76137
      • Site DE49005
  • Bayern
    • Gauting, Bayern, Germany, 82131
      • Site DE49003
    • Wurzburg, Bayern, Germany, 97080
      • Site DE49006
  • Hessen
    • Kassel, Hessen, Germany, 34125
      • Site DE49007
  • Nordrhein-Westfalen
    • Köln, Nordrhein-Westfalen, Germany, 51109
      • Site DE49004
• Hungary
  • Budapest, Hungary, 1121
    • Site HU36007
  • Budapest, Hungary, 1125
    • Site HU36001
  • Fejér
    • Szekesfehervar, Fejér, Hungary, H 8000
      • Site HU36002
  • Tatabánya
    • Tatabanya, Tatabánya, Hungary, H-2800
      • Site HU36003
  • Vas
    • Szombathely, Vas, Hungary, H 9700
      • Site HU36006
  • Veszprém
    • Farkasgyepu, Veszprém, Hungary, 8582
      • Site HU36004
• Italy
  • Bergamo, Italy, 24127
    • Site IT39003
  • Brescia, Italy, 25123
    • Site IT39015
  • Cremona, Italy, 26100
    • Site IT39002
  • Lucca, Italy, 55100
    • Site IT39013
  • Milano, Italy, 20142
    • Site IT39014
  • Piacenza, Italy, 29100
    • Site IT39012
  • Roma, Italy, 00128
    • Site IT39008
  • Lombardia
    • Monza, Lombardia, Italy, 20052
      • Site IT39004
    • Rozzano, Lombardia, Italy, 20089
      • Site IT39009
  • Pordenone
    • Aviano, Pordenone, Italy, 33081
      • Site IT39011
• Japan
  • Niigata, Japan, 951-8122
    • Site JP81022
  • Okayama, Japan, 700-8558
    • Site JP81006
  • Wakayama, Japan, 641-8510
    • Site JP81023
  • Ehime
    • Matsuyama, Ehime, Japan, 791-0280
      • Site JP81018
  • Hirosima [Hiroshima]
    • Hiroshima, Hirosima [Hiroshima], Japan, 730-8518
      • Site JP81013
  • Hokkaidô
    • Sapporo, Hokkaidô, Japan, 003-0804
      • Site JP81014
  • Hukuoka
    • Kurume, Hukuoka, Japan, 830-0011
      • Site JP81008
  • Hukuoka [Fukuoka]
    • Osakasayama-shi, Hukuoka [Fukuoka], Japan, 589-8511
      • Site JP81017
  • Hyogo
    • Kobe, Hyogo, Japan, 650-0047
      • Site JP81024
  • Isikawa [Ishikawa]
    • Kanazawa, Isikawa [Ishikawa], Japan, 920-8530
      • Site JP81015
  • Kanagawa
    • Yokohama, Kanagawa, Japan, 236-0051
      • Site JP81010
    • Yokohama, Kanagawa, Japan, 241-8515
      • Site JP81025
  • Miyagi
    • Sendai, Miyagi, Japan, 980-0873
      • Site JP81012
  • Okayama
    • Kurashiki, Okayama, Japan, 710-8602
      • Site JP81016
  • Osaka
    • Miyakojima-ku, Osaka, Japan, 534-0021
      • Site JP81005
    • Osakasayama-shi, Osaka, Japan, 569-8511
      • Site JP81020
  • Shizuoka
    • Sunto-gun, Shizuoka, Japan, 411-8777
      • Site JP81019
  • Sizuoka [Shizuoka]
    • Sunto-gun, Sizuoka [Shizuoka], Japan, 411-8777
      • Site JP81001
  • Tôkyô [Tokyo]
    • Tokyo, Tôkyô [Tokyo], Japan, 135-8550
      • Site JP81004
  • Ôsaka [Osaka]
    • Hirakata, Ôsaka [Osaka], Japan, 573-1191
      • Site JP81021
    • Osaka-sayama, Ôsaka [Osaka], Japan, 589-8511
      • Site JP81002
• Korea, Republic of
  • Busan Gwang'yeogsi, Korea, Republic of, 48108
    • Site KR82010
  • Chungcheongbugdo
    • Cheongiu, Chungcheongbugdo, Korea, Republic of, 28644
      • Site KR82005
  • Gyeonggi-do
    • Suwon-si, Gyeonggi-do, Korea, Republic of, 16499
      • Site KR82004
  • Gyeonggido
    • Bundang, Gyeonggido, Korea, Republic of, 13620
      • Site KR82017
  • Gyeonggido [Kyonggi-do]
    • Suwon-si, Gyeonggido [Kyonggi-do], Korea, Republic of, 16427
      • Site KR82016
  • Gyeongsangnamdo
    • Jinju-si, Gyeongsangnamdo, Korea, Republic of, 660-702
      • Site KR82009
  • Jeonrabugdo[Chollabuk-do]
    • Jeonju, Jeonrabugdo[Chollabuk-do], Korea, Republic of, 54907
      • Site KR82003
  • Seoul Teugbyeolsi
    • Seoul, Seoul Teugbyeolsi, Korea, Republic of, 130-701
      • Site KR82014
  • Seoul Teugbyeolsi [Seoul-T'ukp]
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 028-481
      • Site KR82002
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 05505
      • Site KR82001
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 135-720
      • Site KR82013
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 139-706
      • Site KR82007
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 152-703
      • Site KR82008
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 156-707
      • Site KR82006
    • Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of, 5368
      • Site KR82015
  • Ulsan Gwang'yeogsi
    • Ulsan, Ulsan Gwang'yeogsi, Korea, Republic of, 682-714
      • Site KR82011
• Malaysia
  • Pahang
    • Kuantan Pahang, Pahang, Malaysia, 25100
      • Site MY60001
  • Pulau Pinang
    • Georgetown, Pulau Pinang, Malaysia, 10450
      • Site MY60002
  • Sarawak
    • Kuching, Sarawak, Malaysia, 93586
      • Site MY60004
• Netherlands
  • Gelderland
    • Arnhem, Gelderland, Netherlands, 6815 AD
      • Site NL31001
  • Noord-Holland
    • Alkmaar, Noord-Holland, Netherlands, 1815 JD
      • Site NL31006
• Peru
  • Arequipa
    • Cercado De Lima, Arequipa, Peru, 04001
      • Site PE51001
  • Lima
    • Miraflores, Lima, Peru, L18
      • Site PE51008
    • San Isidro, Lima, Peru, 1501
      • Site PE51004
• Portugal
  • Coimbra, Portugal, 3041-801
    • Site PT35103
  • Lisboa, Portugal, 1400-038
    • Site PT35102
  • Lisboa
    • Amadora, Lisboa, Portugal, 2720-276
      • Site PT35101
    • Lisbon, Lisboa, Portugal, 1099-023
      • Site PT35104
• Romania
  • Bucuresti, Romania, 031422
    • Site RO40012
  • Sibiu, Romania, 550245
    • Site RO40006
  • Cluj
    • Floresti, Cluj, Romania, 407280
      • Site RO40004
  • Dolj
    • Craiova, Dolj, Romania, 200347
      • Site RO40001
    • Craiova, Dolj, Romania, 200385
      • Site RO40010
  • Prahova
    • Ploiesti, Prahova, Romania, 100010
      • Site RO40007
  • Timis
    • Timisoara, Timis, Romania, 300210
      • Site RO40008
• Russian Federation
  • Saint Petersburg, Russian Federation, 197022
    • Site RU70001
  • Arkhangel'skaya Oblast'
    • Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation, 163045
      • Site RU70012
  • Bashkortostan
    • Ufa, Bashkortostan, Russian Federation, 450054
      • Site RU70017
  • Chelyabinskaya Oblast'
    • Magnitogorsk, Chelyabinskaya Oblast', Russian Federation, 455001
      • Site RU70009
  • Kabardino-Balkarskaya Respublika
    • Nalchik, Kabardino-Balkarskaya Respublika, Russian Federation, 360000
      • Site RU70016
  • Stavropol'skiy Kray
    • Pyatigorsk, Stavropol'skiy Kray, Russian Federation, 357502
      • Site RU70008
• Singapore
  • Central Singapore
    • Singapore, Central Singapore, Singapore, 188770
      • Site SG65001
    • Singapore, Central Singapore, Singapore, 308433
      • Site SG65002
• Spain
  • Madrid, Spain, 28046
    • Site ES34006
  • Madrid, Spain, 28050
    • Site ES34016
  • Ourense, Spain, 32004
    • Site ES34004
  • Sevilla, Spain, 41009
    • Site ES34005
  • Valencia, Spain, 46010
    • Site ES34015
  • Valencia, Spain, 46014
    • Site ES34017
  • Valencia, Spain, 46026
    • Site ES34002
  • Catalunya
    • Barcelona, Catalunya, Spain, 08036
      • Site ES34003
  • Guipúzcoa
    • San Sebastian, Guipuzcoa, Guipúzcoa, Spain, 20014
      • Site ES34008
  • Málaga
    • Malaga, Málaga, Spain, 29010
      • Site ES34010
• Taiwan
  • Kaohsiung, Taiwan, 83301
    • Site TW88606
  • Taichung, Taiwan, 40705
    • Site TW88603
  • Tainan, Taiwan, 70403
    • Site TW88601
  • Tainan, Taiwan, 736
    • Site TW88604
  • Taipei, Taiwan, 100
    • Site TW88608
  • Taipei, Taiwan, 11217
    • Site TW88609
  • Taipei, Taiwan, 11490
    • Site TW88611
  • Taichung
    • Taichung City, Taichung, Taiwan, 40447
      • Site TW88605
  • Taoyuan
    • Taoyuan Hsien, Taoyuan, Taiwan, 33305
      • Site TW88607
• Thailand
  • Chiang Rai, Thailand, 57000
    • Site TH66002
  • Khon Kaen, Thailand, 40002
    • Site TH66004
  • Songkla, Thailand, 90110
    • Site TH66006
  • Chiang Mai
    • Chom Thong, Chiang Mai, Thailand, 50200
      • Site TH66011
  • Krung Thep Maha Nakhon [Bangkok]
    • Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand, 10330
      • Site TH66001
    • Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand, 10400
      • Site TH66012
• Ukraine
  • Chernivets'ka Oblast'
    • Chernivtsi, Chernivets'ka Oblast', Ukraine, 58013
      • Site UA38006
  • Dnipropetrovs'ka Oblast'
    • Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine, 49102
      • Site UA38001
    • Kryvyi Rih, Dnipropetrovs'ka Oblast', Ukraine, 50048
      • Site UA38005
  • Ivano-Frankivs'ka Oblast'
    • Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine, 76000
      • Site UA38008
  • L'vivs'ka Oblast'
    • Lviv, L'vivs'ka Oblast', Ukraine, 79031
      • Site UA38004
  • Volyns'ka Oblast'
    • Lutsk, Volyns'ka Oblast', Ukraine, 43018
      • Site UA38007
  • Zakarpats'ka Oblast'
    • Uzhgorod, Zakarpats'ka Oblast', Ukraine, 88000
      • Site UA38009
    • Uzhgorod, Zakarpats'ka Oblast', Ukraine, 88014
      • Site UA38003
• United Kingdom
  • Sheffield, United Kingdom, S10 2SJ
    • Site GB44003
  • Hertfordshire
    • Middlesex, Hertfordshire, United Kingdom, HA6 2RN
      • Site GB44002
  • Wirral
    • Liverpool, Wirral, United Kingdom, CH63 4JY
      • Site GB44001
• United States
  • California
    • Beverly Hills, California, United States, 90211
      • Site US10029
    • Fountain Valley, California, United States, 90806
      • Site US10025
    • La Jolla, California, United States, 92093
      • Site US10036
    • Loma Linda, California, United States, 92350
      • Site US10051
    • Los Angeles, California, United States, 90033
      • Site US10033
    • Oxnard, California, United States, 93030
      • Site US10031
    • Redondo Beach, California, United States, 90277
      • Site US10052
    • Santa Monica, California, United States, 90404
      • Site US10003
    • Whittier, California, United States, 90603
      • Site US10018
  • Colorado
    • Glenwood Springs, Colorado, United States, 81601
      • Site US10047
  • Florida
    • Aventura, Florida, United States, 33180
      • Site US10013
    • Saint Petersburg, Florida, United States, 33705
      • Site US10048
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Site US10050
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70809
      • Site US10042
  • Maine
    • Scarborough, Maine, United States, 04074
      • Site US10037
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Site US10034
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Site US10030
    • Rochester, Minnesota, United States, 55905
      • Site US10027
  • New Mexico
    • Albuquerque, New Mexico, United States, 87106
      • Site US10045
  • New York
    • Mount Kisco, New York, United States, 10549
      • Site US10012
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States, 18015
      • Site US10021
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Site US10009
    • Nashville, Tennessee, United States, 37232
      • Site US10023
  • Washington
    • Lacey, Washington, United States, 98503
      • Site US10011
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Site US10046

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject agrees not to participate in another interventional study while on treatment.

• Female subject must either:

  • Be of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile
  • Or, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the final study drug administration; And have a negative serum pregnancy test at Screening; And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control (at least 1 of which must be a highly effective method and one must be a barrier method) starting at Screening and throughout the study period and for 28 days after the final study drug administration.
• Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
• Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
• Subject has Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Subject has histologically confirmed locally advanced, metastatic or unresectable Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with mixed histology are eligible if adenocarcinoma is the predominant histology.
• Subject has predicted life expectancy ≥ 12 weeks in the opinion of the investigator.

• Subject must meet all of the following criteria on the laboratory tests that will be analyzed centrally within 7 days prior to the first dose of study drug. In case of multiple laboratory data within this period, the most recent data should be used.

  • Neutrophil count > 1,000/mm3
  • Platelet count ≥ 7.5 x 104 /mm3
  • Hemoglobin > 8.0 g/dL
  • Serum creatinine ˂ 2.0 x upper limit of normal (ULN) or an estimated glomerular filtration rate (eGFR) of > 50 mL/min as calculated by the Cockcroft Gault Method
  • Total bilirubin ˂1.5 x ULN (except for subjects with documented Gilbert's syndrome)
  • AST and ALT ˂ 3.0 x ULN or ≤ 5 x ULN if subject has documented liver metastases
  • Serum sodium level is ≥ 130 mmol/L
• Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examination of a NSCLC FFPE specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and exon 21 L858R mutations are not eligible. A tissue sample from the same block used to determine eligibility by local testing should be available to send to the central lab for confirmatory testing. Subjects randomized based on local results indicating presence of EGFR mutation may remain on study if central results are discordant.
• Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously irradiated lesions will not be considered as measurable lesions.

Exclusion Criteria:

• Subject has received intervening anticancer treatment or previous treatment with chemotherapy for metastatic disease other than palliative local radiation to painful bone metastases completed at least 1 week prior to the first dose of study drug. The administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has finalized ≥ 6 months before the first dose of study drug.
• Subject has received a prior treatment with a therapeutic agent targeting EGFR (e.g., afatinib, dacomitinib, ASP8273, etc).
• Subject has received investigational therapy within 28 days or 5 half-lives prior to the first dose of study drug.
• Subject has received radiotherapy within 1 week prior to the first dose of study drug. If the subject received radiotherapy > 1 week prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.
• Subject has symptomatic central nervous system (CNS) metastasis. Subject with previously treated brain or CNS metastases are eligible provided that the subject has recovered from any acute effects of radiotherapy, does not have brain metastasis related symptoms, is not requiring systemic steroids for at least 2 weeks prior to study drug administration, and any whole brain radiation therapy was completed at least 4 weeks prior to study drug administration, or any stereotactic radiosurgery (SRS) was completed at least 2 weeks prior to study drug administration. Steroid inhaler use or ointment treatment for other concomitant medical disease is permitted.
• Subject has received blood transfusions or hematopoietic factor therapy within 14 days prior to the first dose of study drug.
• Subject has had a major surgical procedure (other than a biopsy) within 14 days prior to the first dose of study drug, or one is planned during the course of the study.
• Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection.
• Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.
• Subject has evidence of an active infection requiring systemic therapy within 14 days prior to the planned first dose of study drug.
• Subject has severe or uncontrolled systemic diseases including uncontrolled hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.
• Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.
• Subject has ongoing cardiac arrhythmia that is Grade ≥ 2 or uncontrolled atrial fibrillation of any grade.
• Subject currently has Class 3 or 4 New York Heart Association congestive heart failure.
• Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
• Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3 months prior to the planned first dose of study drug.
• Subject has concurrent corneal disorder or any ophthalmologic condition which, in the investigator's opinion, makes the subject unsuitable for study participation (i.e., advanced cataracts, glaucoma).
• Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.
• Subject has another past or active malignancy which requires treatment. Prior carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.
• Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation.
• Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of study drug or proton pump inhibitors such as omeprazole within 14 days prior to first dose of study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: ASP8273; Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).	Drug: naquotinib mesilate; Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.; Other Names: ASP8273
ACTIVE_COMPARATOR: erlotinib or gefitinib; Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).	Drug: Erlotinib; Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.; Other Names: Tarceva; OSI-774; Drug: Gefitinib; Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)	PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by IRR. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.	From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Deaths	All events of death after the first study drug administration were included.	From date of randomization up to data cut-off date 21 Dec 2017 (approximately 22 months)
Percentage of Participants With Objective Response (OR)	Percentage of participants with OR was defined as the proportion of participants with best overall response as complete response (CR) or partial response (PR) without confirmation based on the RECIST v1.1 as assessed by the blinded IRR. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.	From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)
PFS as Assessed by the Investigator	PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on RECIST V1.1, as assessed by local investigator. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.	From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)
Percentage of Participants With Disease Control	Percentage of participants with disease control was defined as the proportion of participants whose best overall response was rated as CR, PR or stable disease (SD) among all analyzed participants based on RECIST V1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug.	From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)
Duration of Response (DOR)	DOR was defined as the time from the date of the first response CR/PR (whichever was first recorded) as assessed by IRR to the date of radiographical progression or date of censoring. If a participant had not progressed, the participant was censored at the date of last radiological assessment or at the date of first CR/PR if no post-baseline radiological assessment was available. Results are based Kaplan-Meier estimate.	From date of first response up to data cut-off date 09 May 2017 (approximately 15 months)
Number of Participants With Adverse Events (AEs)	Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.	From first dose of study drug up to 30 days after last dose of study drug taken up to data cut-off 09 May 2017
Functional Assessment of Cancer Therapy - EGFR Inhibitors Subscale (FACT-EGFRI-18) Questionnaire	ACT-EGFRI-18 is an 18-item Likert-scaled questionnaire, used to assess the effect of EGFR inhibitors on quality of life (QoL). The questionnaire is arranged in three HRQL dimensions: physical (seven items), social/emotional (six items), and functional well-being (five items). The response scores ranged from 0 to 4, and the response categories include "not at all", "a little bit", "somewhat", "quite a bit", and "very much." Negatively worded items (e.g., "My skin bleeds easily "or "My skin condition affects my mood") are reverse-scored, so that participants who experience a higher impact of symptom burden on HRQL receive a lower score (range 0-72).	Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC-QLQ-LC13)	The EORTC-QLQ-LC13 is a validated module of the EORTC-QLQ-Core 30, which includes module items that evaluate symptoms such as cough, hemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling hands or feet, hair loss and pain. The total score for the questionnaire ranges from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.	Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)	EORTC-QLQ-LC30 is a 30-item cancer-specific questionnaire with multitrait scaling was used to create five functional domain scales: Physical, Role, Emotional, Social and Cognitive; two items evaluate global QoL; in addition, three symptom scales assess Fatigue, Pain and Emesis; and six single items assess other symptoms. The total score ranges from 0 to 100, with a high score for a functional scale representing a high/healthy level of functioning and a high score for a symptom scale or item representing a high level of symptomatology or problems.	Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)	The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status).	Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

Collaborators and Investigators

• Sponsor: Astellas Pharma Global Development, Inc.

Publications and helpful links

General Publications

• Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1127-1133. doi: 10.1093/annonc/mdz128.

Helpful Links

• Link to results on the Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 11, 2016
• Primary Completion (ACTUAL): December 21, 2017
• Study Completion (ACTUAL): December 21, 2017

Study Registration Dates

• First Submitted: October 26, 2015
• First Submitted That Met QC Criteria: October 26, 2015
• First Posted (ESTIMATE): October 27, 2015

Study Record Updates

• Last Update Posted (ACTUAL): February 12, 2019
• Last Update Submitted That Met QC Criteria: January 24, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Keywords: erlotinib; gefitinib; Non-small cell lung cancer (NSCLC); EGFR mutation; ASP8273; naquotinib
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Erlotinib Hydrochloride; Gefitinib; Naquotinib
• Other Study ID Numbers: 8273-CL-0302; 2015-002894-39 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com

:

• IPD Sharing Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data..
• IPD Sharing Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No